A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Cancer
Interventions: DRUG: GSK2141795
Sponsor: GlaxoSmithKline